Experimental Infectious Diseases and Cancer Research, Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland.
Cancer Immunol Immunother. 2021 Aug;70(8):2275-2289. doi: 10.1007/s00262-020-02835-x. Epub 2021 Jan 28.
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most common childhood malignancy. The two-step BCP-ALL pathogenesis requires in utero-induced chromosomal aberrations and additional mutagenic events for overt leukemia. In mouse models, activation-induced cytidine deaminase (AID/AICDA) was suggested to contribute to BCP-ALL pathogenesis by off-target mutagenic activity. The role of AID in patients, however, remains unclear. Moreover, AID is usually not expressed in precursor B-cells but in germinal center B-cells, where it is induced upon T-helper (Th) cell stimulation. We have previously demonstrated that autologous Th-cells supportively interacted with BCP-ALL-cells. Here, we hypothesize that this interaction additionally induces AID expression in BCP-ALL-cells, leading to off-target mutagenic activity. We show that co-culture with autologous bone marrow Th-cells induced high AICDA expression in primary BCP-ALL-cells. This induction was mediated by a mechanism similar to the induction in mature B-cells involving IL-13/Stat6, CD40L/NF-κB and TGFβ/Smad2/3 signaling. Even though Th-cell-induced AID seemed to be active in vitro in a BCP-ALL reporter cell line, extensive mutational signature analysis revealed no major contribution of AID activity to the mutational landscape in BCP-ALL patients. AID activity was neither detected in mutation clusters nor in known AID targets. Moreover, no recurrently mutated gene showed a relevant enrichment of mutations in the AID motif. Together, the lack of AID-induced mutational consequences argues towards a Th-cell-promoted yet AID-independent BCP-ALL pathogenesis and favors therapeutic research focusing on Th-cell-derived support of BCP-ALL-cells rather than AID-induced effects.
B 细胞前体急性淋巴细胞白血病 (BCP-ALL) 是最常见的儿童恶性肿瘤。两步法 BCP-ALL 发病机制需要宫内诱导的染色体畸变和额外的致突变事件才能发生明显的白血病。在小鼠模型中,激活诱导的胞嘧啶脱氨酶 (AID/AICDA) 被认为通过非靶标致突变活性促进 BCP-ALL 发病机制。然而,AID 在患者中的作用尚不清楚。此外,AID 通常不在前 B 细胞中表达,而是在生发中心 B 细胞中表达,在那里它在 T 辅助 (Th) 细胞刺激下被诱导。我们之前已经证明,自体 Th 细胞与 BCP-ALL 细胞支持性相互作用。在这里,我们假设这种相互作用另外会诱导 BCP-ALL 细胞中 AID 的表达,导致非靶标致突变活性。我们表明,与自体骨髓 Th 细胞共培养诱导原代 BCP-ALL 细胞中 AICDA 的高表达。这种诱导是通过类似于诱导成熟 B 细胞的机制介导的,涉及 IL-13/Stat6、CD40L/NF-κB 和 TGFβ/Smad2/3 信号。尽管 Th 细胞诱导的 AID 在体外 BCP-ALL 报告细胞系中似乎是活跃的,但广泛的突变特征分析并未发现 AID 活性对 BCP-ALL 患者突变景观的主要贡献。在突变簇中或已知的 AID 靶标中均未检测到 AID 活性。此外,没有频繁突变的基因显示 AID 基序中的突变明显富集。总之,缺乏 AID 诱导的突变后果表明,Th 细胞促进而非 AID 依赖的 BCP-ALL 发病机制,并且有利于专注于 Th 细胞衍生的 BCP-ALL 细胞支持而非 AID 诱导效应的治疗研究。